Unraveling the Mechanisms of Non-Response in Patients With and Without Cirrhosis Due to Chronic Hepatitis C
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2017
Price : $35 *
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- 06 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
- 20 Feb 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2016 according to ClinicalTrials.gov record.